EHEva Herrmann

Eva Herrmann

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Eva Herrmann has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial

    by Jörg G. Albert, Katja Lucas, Natalie Filmann, Eva Herrmann, Oliver Schröder, Christoph Sarrazin, Jörg Trojan, Bernd Kronenberger, Jörg Bojunga, Stefan Zeuzem, et al.

    Jörg G. Albert, Katja Lucas, Natalie Filmann et al. A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial. Endoscopy 2014; 46: 857 – 861 DOI 10.1055/s-0034-1377628 Fig. 1 was incorrect: Novel guidewire, success after “Crossover” should read “2” and not “6” as in the Fig. 1 below:

  • Su1729 A Randomized Trial of Guidewire Use for Biliary Stricture Cannulation in Endoscopic Retrograde Cholangiopancreatography (ERCP): Superior Success Rate of a New Single Use Guidewire

    by Joerg G. Albert, Katja Lucas, Natalie Filmann, Eva Herrmann, Oliver Schröder, Joerg Trojan, Christoph Sarrazin, Stefan Zeuzem, Mireen Friedrich-Rust

  • Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

    by Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O. Bechstein, Bernd Kronenberger, Peter R. Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, et al.

    Background & Aims Recurrence of hepatitis C virus (HCV) infection after orthotopical liver transplantation (OLT) is common and associated with reduced graft and patient survival. The protease inhibitor telaprevir may enhance virological response rates in patients after OLT in combination with pegylated interferon‐alfa and ribavirin. Pharmacokinetic studies have shown significant drug–drug interactions between telaprevir and immunosuppression (IS), but telaprevir pharmacokinetics in OLT patients with IS are unknown. Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS. Methods Five patients with HCV genotype 1 infection after OLT and 37 HCV genotype 1‐infected patients patients without prior OLT were treated with telaprevir 2250 mg daily, ribavirin 1000/1200 mg daily and pegylated interferon‐alfa‐2a 180 μg once weekly (triple therapy). Telaprevir plasma concentrations were analysed by liquid chromatography–electrospray‐ionization‐tandem mass spectrometry. HCV RNA was assessed by automatized reverse‐transcription polymerase chain‐reaction. Results Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980–4430) ng/ml and 2520 (1870–8730) ng/ml in patients after OLT and ciclosporin‐ or tacrolimus‐based IS, respectively, as compared to 2790 (1870–3140) in non‐OLT patients (P = 0.3). In one patient with tacrolimus‐based IS, telaprevir dose had to be adjusted to achieve virological response. Telaprevir plasma concentrations were steady at treatment weeks 4, 8 and 12 in patients with and without IS. Conclusions Telaprevir drug monitoring may be necessary in patients with tacrolimus‐based IS in patients with HCV graft infection after OLT.


  • Interobserver agreement of thyroid imaging reporting and data system and realtime elastography for the assessment of thyroid nodules

    by Mireen Friedrich-Rust, Gesine Meyer, Nina Dauth, Christian Berner, Eva Herrmann, Hartmut Schroeter, Katharina Holzer, Lisa Voelkl, Stefan Zeuzem, Joerg Bojunga

    Introduction: Work-up of thyroid nodules remains challenging. Thyroid imaging reporting and data system (TIRADS) has been developed to improve patient management and cost-effectiveness by avoiding unnecessary fine needle aspiration biopsy (FNAB) in patients with thyroid nodules. However, since its publication in JCEM (2009) its clinical use is still very limited and its practicability in clinical practice is questioned. Realtime-elastography (RTE) enables the determination of tissue elasticity and has shown promising results for the differentiation of thyroid nodules. Methods: The aim of the present study was to evaluate the interobserver agreement of TIRADS and RTE. Three blinded observers independently scored stored images of TIRADS and RTE in 114 nodules of 114 patients. In addition, the diagnostic performance of TIRADS and RTE for the diagnosis of malignant thyroid nodules was calculated. Cytology and/or histology was available for all benign (n=99) and histology for all malignant nodules (n=15). Results: The interobserver agreement between the three physicians was only weak for TIRADS categories 2–5 (Cohen’s κ=0.27, P=0.000001) and TIRADS categories 2/3 vs 4/5 (ck=0.25, P=0.0020). The interobserver agreement was substantial for RTE scores 1–4 (ck=0.66, PP<0.000001). 92–100% of patients with TIRADS 2 had benign lesions, while 28–42% with TIRADS 5 had malignant cytology/histology. The negative predictive value (NPV) was 92–100% for TIRADS using TIRADS categories 4 and 5 and 96–98% for RTE using score 3 and 4 for the diagnosis of malignancy, respectively. However, only 11–42% of nodules were in TIRADS-categories 2 and 3, as compared to 58–60% with RTE-score 1 and 2. Conclusions: Interobserver agreement of TIRADS is only fair. TIRADS and RTE have high NPV for excluding malignancy in the diagnostic work-up of thyroid nodules. However, only 1/3 of FNABs could be avoided using TIRADS as compared to 60% using RTE. Prospective multicenter studies are needed to further evaluate the clinical utility of both methods.


    • 1 December 2012
      • Vol. 21  (4) , 367-73

    Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C.

    by Nicole Forestier, Antonia Gaus, Eva Herrmann, Christoph Sarrazin, Joerg Bojunga, Thierry Poynard, Joerg Albert, Ludmila Gerber, Maximilian-David Schneider, Georg Dultz, et al.

    Antiviral therapy can stop progression of liver fibrosis and partially reverse it. Non-invasive methods have shown good diagnostic accuracies for the assessment of liver fibrosis. First studies have shown that transient elastography (TE) can be used to monitor fibrosis after antiviral therapy. Acoustic-Radiation-Force-Impulse (ARFI)-Imaging is an elastography method integrated in a conventional ultrasound machine. The aim of the present study was to demonstrate a significant difference of ARFI-values in patients with sustained-virological-response (SVR) as compared to patients without. Ninety-eight patients infected with chronic hepatitis C virus (HCV) who had completed antiviral treatment were prospectively included in the study and received ARFI-imaging, TE and laboratory evaluation. Significantly lower ARFI and TE values were observed for 47 patients with SVR as compared to 51 patients without SVR (1.37 m/s vs. 2.00,p=0.0021; 4.9 kPa vs. 11.1 kPa,p<0.001), respectively. Liver stiffness values and shear wave velocity using ultrasound-based elastography methods are different in patients with SVR as compared to patients without SVR after antiviral therapy for chronic hepatitis C. However, the causes of this difference (fibrosis regression, cytolysis, baseline fibrosis) remain unclear and require further evaluation in future studies.


  • HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a

    by Christian M. Lange, Simone Susser, Eva Herrmann, Ursula Karey, Tara L. Kieffer, Ann D. Kwong, Janke Schinkel, Henk W. Reesink, Stefan Zeuzem, Christoph Sarrazin

    Background. The extensive heterogeneity of the hypervariable region-1 (HVR-1) of hepatitis C virus (HCV) evidences the high genetic flexibility of HCV and was shown to be associated with virologic response to interferon-α-based therapies. However, the evolution of HVR-1 heterogeneity during treatment with directly acting antivirals has not been studied. Methods. Clonal sequence analysis of HVR-1 quasispecies in the serum of patients who were treated with telaprevir (3 × 750 mg/day) alone, telaprevir plus pegylated interferon-α-2a (pegIFN-α-2a), or pegIFN-α-2a plus placebo for 14 days was performed. HVR-1 heterogeneity, expressed as Shannon complexity and Hamming distance, was analyzed with virologic response and with the emergence of variants associated with resistance to telaprevir. Results. HVR-1 heterogeneity at baseline was not associated with response to telaprevir-based therapy (Shannon complexity 0.34 vs. 0.55, p = 0.38; Hamming distance 0.15 vs. 0.23, p = 0.51; for patients with or without viral breakthrough, respectively). No significant changes in HVR-1 complexity were observed from baseline to day 4 of therapy in patients in whom a continued decline in HCV RNA was observed (Shannon complexity = 0.55 vs. 0.51, p = 0.67; Hamming distance = 0.23 vs. 0.25, p = 0.81, respectively). This was similar in patients with viral breakthrough associated with telaprevir-resistant variants (Shannon complexity = 0.34 vs. 0.42, p = 0.68; Hamming distance = 0.15 vs. 0.2, p = 0.50, at baseline and day 4, respectively). Conclusions. Baseline and on-treatment HVR-1 heterogeneity are not associated with early viral response to telaprevir-based therapy.


  • Influence of amantadine on CD81 expression on lymphocytes in chronic hepatitis C

    by Martin-Walter Welker, Michael von Wagner, Dana Ochs, Vincent Zimmer, Wolf Peter Hofmann, Albrecht Piiper, Rolf W. Hartmann, Eva Herrmann, Stefan Zeuzem, Bernd Kronenberger


  • T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a

    by Bernd Kronenberger, Eva Herrmann, C. Chen, M. Fiscella, Mani Subramanian, John McHutchison, Yves Benhamou, Mark Sulkowski, David R. Nelson, Stefan Zeuzem

  • Top Cited Papers

    Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis

    by Mireen Friedrich–Rust, Mei–Fang Ong, Swantje Martens, Christoph Sarrazin, Joerg Bojunga, Stefan Zeuzem, Eva Herrmann


  • Open Access

    Impact of NS5A Sequences of Hepatitis C Virus Genotype 1a on Early Viral Kinetics during Treatment with Peginterferon‐α2a plus Ribavirin

    by Francesca Dal Pero, Kwok H. Tang, Martina Gerotto, Gladis Bortoletto, Emma Paulon, Eva Herrmann, Stefan Zeuzem, Alfredo Alberti, Nikolai V. Naoumov

    Background. Hepatitis C virus (HCV) genotype 1 is the most prevalent genotype in Western countries, and treatment with pegylated interferon (pegIFN) plus ribavirin fails in 50%–60% of patients. Genetic variability within the NS5A dsRNA-dependent protein kinase binding domain (PKRbd) of HCV-1b has been associated with responsiveness to IFN-α. Little is known about NS5A sequences of HCV-1a.We investigated whether genetic variability of HCV-1a NS5A correlates with the early HCV kinetics during treatment. Methods. Twenty-four treatment-naive, HCV-1a-infected patients were treated with standard doses of pegIFNα2a plus ribavirin. HCV viremia was quantitated at days 0, 1, 2, and 3 and weeks 1, 2, 4, 8, and 12 of treatment. According to HCV kinetics, patients were classified as early rapid responders, early moderate responders, or early slow responders. The full-length HCV NS5A was sequenced at baseline and at week 1. Results. At baseline, variability of the NS5A C terminus (concentrated in the PKRbd) is associated with interferon efficacy but not with the second phase of the early viral decline that has been associated with a sustained virologic response. Comparisons between baseline and week-1 full-length sequences did not show significant increases in mutations. Conclusions. Genetic variability of HCV-1a NS5A does not predict responsiveness to IFN-α. Differences in early kinetics during combination therapy are not due to selection of IFN-resistant HCV strains.